Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX’s obesity pill lost up to 8.2% in body weight after 28 days.

This article was originally published here.